These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2851676)
1. Cardiovascular pharmacology of RS-1893, an orally active cardiotonic agent with arterial and venous vasodilator actions. Miyake S; Shiga H; Koike H; Mizuno H; Yorikane R; Oda T; Iijima Y; Kumakura S; Morisawa Y Jpn J Pharmacol; 1988 Jul; 47(3):273-83. PubMed ID: 2851676 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties. Mochizuki N; Uchida S; Miyata H J Cardiovasc Pharmacol; 1993 Jun; 21(6):983-95. PubMed ID: 7687727 [TBL] [Abstract][Full Text] [Related]
3. Arterial and venous vasodilator actions of RS-1893, a novel cardiotonic agent, in the hindlimb preparation of the dog. Miyake S; Shiga H; Koike H J Cardiovasc Pharmacol; 1989 Oct; 14(4):526-33. PubMed ID: 2478765 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular pharmacology of 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. Narimatsu A; Kitada Y; Satoh N; Suzuki R; Okushima H Arzneimittelforschung; 1987 Apr; 37(4):398-406. PubMed ID: 3606694 [TBL] [Abstract][Full Text] [Related]
6. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005. Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology of LY195115, a potent, orally active cardiotonic with a long duration of action. Hayes JS; Pollock GD; Wilson H; Bowling N; Robertson DW J Cardiovasc Pharmacol; 1987 Apr; 9(4):425-34. PubMed ID: 2438505 [TBL] [Abstract][Full Text] [Related]
8. In vivo pharmacological studies with SK&F 94836, a potent inotrope/vasodilator with a sustained duration of action. Gristwood RW; Comer MB; Eden RJ; Taylor EM; Turner JA; Wallduck M; Owen DA Br J Pharmacol; 1988 Apr; 93(4):893-901. PubMed ID: 3390657 [TBL] [Abstract][Full Text] [Related]
9. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 2nd communication: in vivo cardiovascular effects and bioavailability in dogs. Yoshimura A; Koide Y; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M Arzneimittelforschung; 1999 May; 49(5):407-11. PubMed ID: 10367102 [TBL] [Abstract][Full Text] [Related]
10. Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig. Duncker DJ; Hartog JM; Levinsky L; Verdouw PD Br J Pharmacol; 1987 Jul; 91(3):609-15. PubMed ID: 3607369 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular properties of MS-857, a new and potent cardiotonic agent, on normal and failing hearts. Maruyama M; Kamiya J; Kaiho T; Kobari T J Cardiovasc Pharmacol; 1988; 12(5):579-86. PubMed ID: 2468058 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride. Sellin LC; Alajoutsijärvi A; Törnquist K; Fraser M; Pippuri A; Ojala I Arzneimittelforschung; 1988 Dec; 38(12):1787-9. PubMed ID: 2854467 [TBL] [Abstract][Full Text] [Related]
14. Effects of RS-1893, a novel cardiotonic agent, on central and peripheral hemodynamics in anesthetized rats. Miyake S; Shiga H; Sada T; Oizumi K; Koike H Jpn J Pharmacol; 1989 Dec; 51(4):577-80. PubMed ID: 2615052 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and adenylate cyclase stimulant properties of NKH477, a novel water-soluble forskolin derivative. Hosono M; Takahira T; Fujita A; Fujihara R; Ishizuka O; Tatee T; Nakamura K J Cardiovasc Pharmacol; 1992 Apr; 19(4):625-34. PubMed ID: 1380607 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs. Ohhara H; Ogawa T; Takeda M; Katoh H; Daiku Y; Igarashi T Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742 [TBL] [Abstract][Full Text] [Related]